| sodium deoxycholate / Generic mfg. |
NCT00422188: Deoxycholic Acid Injection for the Treatment of Superficial Lipomas |
|
|
| Completed | 1 | 16 | US | Deoxycholic Acid Injection, ATX-101, Sodium deoxycholate, Placebo | Kythera Biopharmaceuticals | Lipoma | 11/07 | 11/07 | | |
NCT00618709: Dose-Escalation Safety and Pharmacokinetic Study of ATX-101 |
|
|
| Completed | 1 | 24 | US | ATX-101 | Kythera Biopharmaceuticals | Healthy | 12/08 | 01/09 | | |
| Completed | 1 | 14 | US | ATX-101 | Kythera Biopharmaceuticals | Characteristics of Subcutaneous Fat | 03/09 | 04/09 | | |
NCT01319916: Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue |
|
|
| Completed | 1 | 10 | US | ATX-101 | Kythera Biopharmaceuticals | Healthy | 01/11 | 01/11 | | |
NCT01320761: A Study to Assess Injection Comfort of Two Formulations of ATX-101 |
|
|
| Completed | 1 | 24 | US | ATX-101-BA-free, ATX-101-BA | Kythera Biopharmaceuticals | Healthy | | | | |
NCT01462786: To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101 |
|
|
| Completed | 1 | 5 | US | ATX-101 | Kythera Biopharmaceuticals | Healthy | 11/11 | 12/11 | | |
NCT01632917: Open-Label Pharmacokinetic Study of Final Formulations of ATX-101 |
|
|
| Completed | 1 | 24 | US | ATX-101 - U.S., ATX-101 - EU | Kythera Biopharmaceuticals | Healthy | 07/12 | 07/12 | | |
| Completed | 1 | 218 | US | ATX-101 (10 mg/ml), ATX-101 (20 mg/ml), Moxifloxacin (400 mg), Placebo vehicle (PBS) | Kythera Biopharmaceuticals | Healthy | 02/13 | 06/13 | | |
NCT06132165: Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Completed | 1 | 13 | US | Deoxycholic Acid, Kybella, Polidocanol, Asclera, 1064nm Nd:YAG laser, 755nm Alexandrite Laser | Massachusetts General Hospital, Johns Hopkins University | Neurofibromatosis 1 | 07/25 | 07/25 | | |
NCT06120036: Dosing and Tolerability of Deoxycholic Acid Vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Completed | 1 | 20 | US | Kybella, Asclera | Massachusetts General Hospital, Johns Hopkins University | Neurofibromatosis 1 | 01/25 | 01/25 | | |
NCT04730583: Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Completed | 1 | 34 | US | Kybella, 1064nm laser, 755nm Alexandrite Laser | Massachusetts General Hospital, Johns Hopkins University | Cutaneous Neurofibroma | 04/24 | 04/24 | | |
NCT06756490: A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation |
|
|
| Recruiting | 1 | 30 | RoW | HY-2003 (10 mg/ml), BELKYRA and placebo, HY-2003 (5 mg/ml) and placebo | Sichuan Huiyu Pharmaceutical Co., Ltd, Peking Union Medical College Hospital, First Affiliated Hospital Xi'an Jiaotong University | Moderate or Severe Submental Fullness | 02/26 | 02/26 | | |
NCT06300502: Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) |
|
|
| Enrolling by invitation | 1 | 15 | US | Kybella, Deoxycholate, Deoxycholic acid | Massachusetts General Hospital, Johns Hopkins University, Neurofibromatosis Therapeutic Acceleration Program | Neurofibromas, Cutaneous, Neurofibromatosis 1 | 02/26 | 02/26 | | |
NCT07237425: Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma |
|
|
| Recruiting | 1 | 56 | RoW | Ronkyla Plus, Placebo, Normal saline, Kybella, deoxycholic acid, ATX-101 | Glonova Pharma Co., Ltd, T-TOP Clinical Research Co., Ltd. | Lipoma, Submental Fullness | 11/26 | 01/27 | | |
NBT-QYDS-002, ChiCTR2500107600: Randomized, blind, parallel, and positive-controlled Phase I clinical trials of subcutaneous fat layer injection treatment in people with excess subcutaneous fat accumulation in Chinese jaws |
|
|
| Not yet recruiting | 1 | 40 | | Administer the experimental drug deoxycholic acid injection to the subjects, with a concentration of 10mg/ml deoxycholic acid injection. Subcutaneous inject 0.2m of the injection at each injection point, with a 1.5cm interval between each two injection points.; Administer the experimental drug deoxycholic acid injection to the subjects, with a concentration of 10mg/mL deoxycholic acid injection. Subcutaneous inject 0.2ml of the injection at each injection point, with a 1.0cm interval between each two injection points; Give the subject a positive control drug deoxycholic acid injection (Belkyra) deoxycholic acid injection;; Administer the experimental drug deoxycholic acid injection to the subjects, with a concentration of 10mg/m deoxycholic acid injection. Subcutaneous inject 0.1ml of the injection solution at each injection point, with a 1.0cm interval between every two injection points. | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Beijing Norbert Biotechnology Co., Ltd. | Improved appearance of moderate to severe to heavy bulge or fullness of under the chin of adults | | | | |
